Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Apatinib Mesylate in Unresectable Hepatocellular Carcinoma: NCT07749859 Clinical Landscape Report 2026
16 September 2026
NCT07749859 clinical landscape for Unresectable Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
NBL-023 in Dermatitis, Atopic: NCT07746817 Clinical Landscape Report 2026
16 September 2026
NCT07746817 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab govitecan-hziy in ALK positive Non-Small Cell Lung Cancer: NCT07750704 Clinical Landscape Report 2026
16 September 2026
NCT07750704 clinical landscape for ALK positive Non-Small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
JNJ-98768111 in Advanced Prostate Carcinoma: NCT07746713 Clinical Landscape Report 2026
16 September 2026
NCT07746713 clinical landscape for Advanced Prostate Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anlotinib Dihydrochloride in Unresectable Hepatocellular Carcinoma: NCT07746960 Clinical Landscape Report 2026
16 September 2026
NCT07746960 clinical landscape for Unresectable Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
ACG102 in Systemic Lupus Erythematosus: NCT07749430 Clinical Landscape Report 2026
16 September 2026
NCT07749430 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RO7845860 (F. Hoffmann-La Roche Ltd.) in Multiple sclerosis relapse: NCT07749157 Clinical Landscape Report 2026
16 September 2026
NCT07749157 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mepolizumab in Pulmonary Disease, Chronic Obstructive: NCT07749001 Clinical Landscape Report 2026
16 September 2026
NCT07749001 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
GT802 (Vivacta Biotechnology (Shanghai) Co., Ltd.) in Multiple Sclerosis: NCT07748637 Clinical Landscape Report 2026
16 September 2026
NCT07748637 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma: NCT07748611 Clinical Landscape Report 2026
16 September 2026
NCT07748611 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
CHM-029 in Acute myeloid leukemia with mutated NPM1: NCT07751991 Clinical Landscape Report 2026
16 September 2026
NCT07751991 clinical landscape for Acute myeloid leukemia with mutated NPM1: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Belantamab mafodotin in Relapse multiple myeloma: NCT07748689 Clinical Landscape Report 2026
16 September 2026
NCT07748689 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.